Patent 11939372 was granted and assigned to Amgen on March, 2024 by the United States Patent and Trademark Office.
Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.